共 50 条
Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis
被引:9
作者:
Pan, Rui
[1
]
Cheng, Jinping
[2
]
Lai, Kelin
[1
]
Huang, Qing
[3
]
Wu, Hui
[1
]
Tang, Yamei
[2
]
机构:
[1] Huizhou Hlth Sci Polytech, Dept Nursing, Huizhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huizhou Hlth Sci Polytech, Dept Basic Courses, Huizhou, Guangdong, Peoples R China
基金:
国家重点研发计划;
关键词:
Intracranial hemorrhage;
Vitamin K antagonists;
Prothrombin complex concentrate;
Meta-analysis;
FRESH-FROZEN PLASMA;
INTERNATIONAL NORMALIZED RATIO;
FACTOR-IX COMPLEX;
INTRACEREBRAL HEMORRHAGE;
ANTICOAGULATION REVERSAL;
WARFARIN;
GUIDELINES;
MANAGEMENT;
COAGULOPATHY;
ENLARGEMENT;
D O I:
10.1007/s10072-019-3726-x
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Background Prothrombin complex concentrate (PCC) is the treatment of choice in vitamin K antagonist-associated intracranial hemorrhage (VKA-ICH). However, the efficiency and safety associated with their use remain unclear. Aims This study aimed to assess the current evidence of the clinical outcomes in patients with VKA-ICH treated with or without PCC. Summary of review A meta-analysis was conducted. Two randomized controlled trials and 19 observational studies were included. PCC use demonstrated a significant increased likelihood of international normalized ratio (INR) normalization (OR=3.76; 95% CI 1.74-8.12), shortened time to INR correction (MD=-1.30; 95% CI -2.08 to -0.53) and reduction of hematoma expansion (HE) rate (OR=0.37; 95% CI 0.23-0.60). Although PCC use revealed a statistical reduction at 30-day mortality (OR=0.62; 95% CI 0.50-0.78), the result was inconsistent with mortality at discharge (OR=1.03; 95% CI 0.68-1.57) and 90-day follow-up (OR=0.50; 95% CI 0.24-1.07), both of which yielded no significant difference. When subgroup analyses were performed focus on PCC only treatment with FFP, no statistically significant difference was observed in 30-day mortality (OR=0.43; 95% CI 0.11-1.71) as well. Besides, significant difference was not found in neurologic improvement at discharge (OR=1.85; 95% CI 0.32-10.75), 30-day follow-up (OR=3.00; 95% CI 0.93-9.70), or 90-day follow-up (OR=1.55; 95% CI 0.84-2.86). No statistically significant difference was noted in the risk of thromboembolism following PCC administration (OR=0.61; 95% CI 0.23-1.63). Conclusions PCC use for VKA-ICH reversal was associated with a significant reduction in INR and HE rate, without an increased risk of thromboembolic events. However, this reduction was not associated with improvement in neurologic deficits or overall survival. Well-designed randomized trials with special considerations to the aspect are necessary.
引用
收藏
页码:813 / 827
页数:15
相关论文
共 50 条